<DOC>
	<DOCNO>NCT00686556</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total marrow irradiation donor umbilical cord blood hematopoietic stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I trial study side effect best dose total marrow irradiation give together combination chemotherapy umbilical cord blood hematopoietic stem cell transplant treat patient acute leukemia , acute myeloid leukemia multiple myeloma respond previous therapy .</brief_summary>
	<brief_title>Total Marrow Irradiation Refractory Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose total marrow irradiation ( TMI ) deliver image-guided tomographic intensity-modulated radiotherapy administer combination myeloablative chemotherapy patient undergo double umbilical cord blood ( UCB ) transplantation hematopoietic stem cell refractory acute leukemia . Secondary - Determine incidence engraftment ( defined achievement neutrophil count &gt; 500/uL 42 day transplantation ) . - Determine incidence platelet engraftment 6 month 1 year transplantation . - Evaluate incidence complete donor chimerism relative contribution UCB unit donor engraftment within first 100 day transplantation . - Determine incidence transplantation-related mortality ( TRM ) 6 month treatment TMI-containing myeloablative conditioning regimen . - Determine incidence grade II-IV grade III-IV acute graft-versus-host disease ( GVHD ) 100 day transplantation . - Determine incidence chronic GVHD 1 year transplantation . - Determine incidence relapse 1 year transplantation . - Determine survival disease-free survival 1 2 year transplantation . - Assess durability remission base presence rapid early response ( defined clearance leukemic blast bone marrow 21 day transplantation ) . OUTLINE : This dose-escalation study total marrow irradiation ( TMI ) . - Myeloablative conditioning regimen : Patients receive fludarabine phosphate IV 1 hour daily 3 day day -12 -6 cyclophosphamide IV daily 2 day day -11 -6 . Patients undergo TMI daily 4-8 day day -8 -1 . - Donor umbilical cord blood ( UCB ) transplantation : Patients undergo single-unit double-unit donor UCB transplantation day 0 . Patients receive filgrastim ( G-CSF ) IV subcutaneously daily begin day 1 continue blood count recover . - Related Donor : Related donor bone marrow collect ( target cell dose 5x10^8 nucleated cells/kg recipient weight , minimum 3x10^8 nucleated cells/kg recipient weight ) infuse without process day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour orally 2-3 time daily begin day -3 continue day 100 , follow taper day 180 , absence GVHD . Patients also receive mycophenolate mofetil IV orally 2-3 time daily begin day -3 continue day 30 ( 7 day engraftment ) , absence acute GVHD . Patients follow periodically 2 year transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Acute lymphoblastic leukemia ≥ Complete remission 2 ( CR2 ) ( adults ≥ 18 year ≤ 55 year ) CR2 pediatrics ( define &lt; 18 year ) &lt; 12 month duration first remission ≥ CR3 remission ( pediatric patient &lt; 18 year ) T cell leukemia ≥ CR2 Evidence pretransplant minimal residual disease ( MRD ) flow cytometry , FISH cytogenetics Myelodysplastic syndrome ≤ 55 year age ≥ 10 % blast , responsive hypomethylating agent and/or conventional therapy Acute myeloid leukemia Not remission ( pediatric patient &lt; 18 year ) Not remission ( 1030 % blast bone marrow adult patient ≥18 year ≤ 55 year ) Evidence pretransplant minimal residual disease ( MRD ) flow cytometry , FISH cytogenetics Multiple myeloma No prior autologous transplant fit one follow disease category : Early disease stage ( CR1/PR1 ) highrisk molecular feature Early disease stage ( CR1/PR1 ) highrisk clinical feature Late disease stage ( CR2/PR2+ ) highrisk clinical feature Other high risk hematologic malignancy approve 2 hematology/oncology BMT physicians Patients prior CNS involvement eligible provide treated remission . CNS therapy ( chemotherapy radiation ) continue medically indicate protocol . Have acceptable organ function within 14 day study registration define : Renal : glomerular filtration rate &gt; 60ml/min/1.73m2 Hepatic : bilirubin , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , Alkaline phosphatase ( ALP ) &lt; 5 x upper limit normal ( ULN ) Pulmonary function : Carbon Monoxide Diffusing Capacity correct ( DLCOcorr ) &gt; 50 % normal , ( oxygen saturation [ &gt; 92 % ] use child pulmonary function test ( PFT 's ) obtain ) Cardiac : leave ventricular ejection fraction ≥ 45 % echocardiogram ( ECHO ) multi gate acquisition scan ( MUGA ) Karnofsky performance status ( PS ) &gt; 80 % age 16 year old Lansky Play Score &gt; 50 &lt; 16 year An acceptable source stem cell accord current University Minnesota BMT program guideline : UCB graft compose two partially HLA match unit . Each unit must match 46 HLA loci recipient . If two match unit available , single HLA 46 match unit may use adequate cell dose total graft dose must &gt; 3 x 107 MNC/kg HLAmatched relate donor ( 6/6 5/6 antigen match ) HLAmatched unrelated adult donor ( previously identify ) Women childbearing potential must agree use adequate contraception ( diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) duration treatment . Voluntary write consent Active uncontrolled infection time enrollment document fungal infection within 3 month . Evidence Human immunodeficiency virus ( HIV ) infection Pregnant breast feeding . The agent use study may teratogenic fetus information excretion agent breast milk . All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy . Prior myeloablative transplant within last 6 month Prior total body irradiation ( TBI ) make total marrow irradiation ( TMI ) feasible</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
</DOC>